GUFICBIO Intraday Analysis...

GUFICBIO Share Price

Open 58.25 Change Price %
High 58.25 1 Day -0.70 -1.22
Low 56.25 1 Week 1.50 2.72
Close 56.55 1 Month 3.15 5.90
Volume 39917 1 Year 18.60 49.01
52 Week High 63.70
52 Week Low 32.10
GUFICBIO Important Levels
Resistance 2 58.40
Resistance 1 57.64
Pivot 57.02
Support 1 55.46
Support 2 54.70
NSE INDIA Most Active Stocks
SUZLON 17.00 -2.86%
VISESHINFO 0.25 25.00%
JPASSOCIAT 10.30 3.00%
ICICIBANK 257.15 -0.16%
ESL 5.55 2.78%
ESL 5.55 2.78%
ESL 5.55 2.78%
ESL 5.55 2.78%
GMRINFRA 12.80 1.99%
HINDALCO 187.15 3.00%
NSE INDIA Top Gainers Stocks
VISESHINFO 0.25 25.00%
HINDNATGLS 136.65 19.97%
PRESSMN 53.25 19.93%
OISL 7.25 19.83%
TRENT 245.90 17.07%
ELAND 27.40 12.76%
HOTELRUGBY 4.60 12.20%
KOLTEPATIL 95.15 11.35%
AYMSYNTEX 91.40 10.72%
UNIVCABLES 115.60 10.67%
NSE INDIA Top Losers Stocks
FCSSOFT 0.25 -16.67%
UVSL 0.45 -10.00%
ASHIMASYN 15.60 -7.96%
MVL 0.60 -7.69%
MVL 0.60 -7.69%
ICSA 3.20 -7.25%
ICSA 3.20 -7.25%
ZENITHBIR 0.65 -7.14%
3IINFOTECH 6.10 -6.87%
GTLINFRA 4.15 -6.74%

Gufic Biosciences Limited (NSE: GUFICBIO)

GUFICBIO Technical Analysis 4
As on 24th Jan 2017 GUFICBIO Share Price closed @ 56.55 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 44.05 & Buy for SHORT-TERM with Stoploss of 51.09 we also expect STOCK to react on Following IMPORTANT LEVELS.
GUFICBIO Target for January
1st Target up-side 60.97
2nd Target up-side 66.41
3rd Target up-side 71.85
1st Target down-side 45.43
2nd Target down-side 39.99
3rd Target down-side 34.55
GUFICBIO Synopsis Technicals View
50 Day EMA N/A (Short Term)
100 Day EMA N/A (Mid Term) N/A
200 Day EMA N/A (Long Term) N/A
MACD (12 26 9) N/A N/A
RSI (14) N/A N/A
MFI (14) N/A N/A
CCI (20) N/A N/A
ADX (14) N/A N/A
10 Day Avg Volume N/A
GUFICBIO Other Details
Segment EQ
Market Capital 0.00
Sector Healthcare
Industry Drug Manufacturers - Major
Offical website
Kamala Bhavan II
Shop - 37, First Floor
Mumbai, 400069
GUFICBIO Latest News
Limited Review for Dec 31, 2014   Hindu Business Line   - 03rd Mar 15
Proposed Bank Strikes   Hindu Business Line   - 17th Feb 15
Gufic Bio standalone Dec '14 sales at Rs 34.34 crore   - 17th Feb 15
BSE Breaches 25.8k Mark; Metals, Goods, Auto and Power Stocks Fall   International Business Times, India Edition   - 04th Jul 14
NPPA sends notices in 89 cases of overcharging to recover   - 22nd Apr 14
Gufic BioSciences Ltd Recommends Dividend   Reuters Key Development   - 31st May 13
Cops hunt for fake drug maker   Times of India   - 24th Feb 09
Interactive Technical Analysis Chart Gufic Biosciences Limited ( GUFICBIO NSE INDIA )
Java support must be enabled in order to display FnCharts.
You can download Java from
Your Comments and Response on Gufic Biosciences Limited
GUFICBIO Business Profile
Gufic Biosciences (GUFICBIO) is a pharmaceuticals and biosciences company. Incorporated in 1984 as Central Finance, the company got its current name on Jun. 05, 2000. The company operates in the segments of pharma, healthcare, bio-technology, seeds, herbal, R&D, and bulk drugs. The company provides pharma medicines for diarrhoea (Ridol), episiotomy (Zad-g), anemia (Optifer), infections (Lotril), inflammation (Valsafe)...etc. The healthcare segment provides consumer and personal hygiene products like roll-ons for cold and sanitary napkins like Shapers. The biotechnology segment produces high-yielding and elite planting material of medicinal and other herbal plants using tissue culture techniques. The tissue culture facility produces five million plants per annum. The company has two green houses of 800 sq. m. Production includes banana, potato, sugarcane, date palm, jatropha, and bixa (source of natural food color). It brings out hybrid varieties of major vegetable seeds like tomato, chilli, cabbage, cauliflower, capsicum, coriander, bhendi, bottle gourd, bitter gourd, ridge gourd, brinjal, cucumber and watermelon. The company provides herbal and ayurvedic medicines for muscular pains (Sallaki); menstrual excesses (Eugynin); hyperacidity, gastritis, and chronic fungal dyspepsia (Zulcer), aches and pains (Rumastal-forte), liver problems (Livpar), constipation (Laxive), and cough (Kofend Syrup). Bulk drugs include anesthetics (lidocaine), antifungals (econazole, miconazole, ketokonazole), antiielmintic (mebendazole, polymorph), cathartic (castor oil), and food colors. The company has its facilities in Vile Parle, Mumbai and a plant in Navsari, Gujarat. The R&D Centre is a state-of-the-art research laboratory and provides total product development by developing new pharmaceutical products, new drug delivery systems, and new platform technologies. The functional areas are formulation development, analytical development, packaging development and documentation. The current market capitalization stands at Rs 44.48 crore. The company has reported a standalone sales of Rs 29.03 crore and a Net Profit of Rs 1.15 crore for the quarter ended September 2013. The company management includes Jayesh P Choksi - Chairman & Managing Director, Pranav J Choksi - Executive & Wholetime Director, M G Dhapalapur - Executive & Wholetime Director, Sharat S Gandhi - Ind. Non-Executive Director, Ashok M Tarale - Ind. Non-Executive Director, Khantilal N Sanghavi - Ind. Non-Executive Director, Pankaj J Gandhi - Additional Director, Jagdish D Shah - Additional Director. The Registered office is at Shop - 37, First Floor, Kamala Bhavan II, Swami Nityanand Road, Mumbai, Maharashtra - 400069.